Oral Semaglutide Works Well in Japanese Adults with Type 2 Diabetes — Including Those Over 75 | Research

The takeaway

In 624 Japanese adults with T2DM in routine clinical practice, oral semaglutide reduced HbA1c by 0.7% and body weight by 2.8 kg over 34-44 weeks, with similar benefits in patients aged 75 and older.

−0.7% HbA1c
Oral semaglutide in 624 Japanese adults in routine clinical practice, with meaningful reductions maintained even in patients aged 75+

What the researchers found

Oral semaglutide reduced HbA1c by −0.7% and body weight by −2.8 kg in 624 Japanese T2DM adults over 34-44 weeks. Benefits were maintained in patients ≥75 years (HbA1c −0.5%, weight −2.7 kg). 25.8% reported adverse events, mostly gastrointestinal.

Why it matters

Real-world evidence in an Asian population is critical because drug metabolism and diabetes phenotypes differ from Western populations studied in clinical trials. Confirming efficacy and safety in elderly Japanese patients addresses a significant evidence gap.

The numbers in context

Follow-up: 34-44 weeks. Population: injection-naïve T2DM adults in Japanese clinical practice.

How the study worked

Non-interventional, multicenter, prospective, real-world study. 624 adults naïve to injectable glucose-lowering therapies initiated oral semaglutide in routine practice and were followed for 34-44 weeks. Subgroup analyses for age <75 and ≥75 years.

Who was studied

Injection-naïve Japanese adults with type 2 diabetes

What this study cannot tell us

Non-interventional study without a control group. Only 34-44 weeks of follow-up. Japanese population may not be fully generalizable to other Asian or non-Asian groups. Selection bias — only patients prescribed oral semaglutide in practice were included.

How to read the evidence

Moderate evidence from a large prospective real-world study (624 participants). Strengthened by routine clinical practice setting but limited by lack of a control group.

When this study was published

Published in 2024; provides current real-world evidence for oral semaglutide in Japan.

The bigger picture

Oral GLP-1 agonists eliminate the injection barrier that many patients face. Real-world studies like PIONEER REAL confirm that the pill form works outside controlled clinical trial settings, supporting broader adoption for patients who refuse or cannot manage injectable therapies.

Questions still open

How do the real-world results compare to the Japanese subgroup in the PIONEER randomized clinical trials?
What is the long-term (>1 year) adherence and efficacy of oral semaglutide in Japanese practice?
Does oral semaglutide reduce cardiovascular events in this population?

Common questions

Does the oral semaglutide pill work as well as the injection?

The real-world results (−0.7% HbA1c, −2.8 kg weight loss) are somewhat more modest than injectable semaglutide results, which is expected given lower oral bioavailability. However, the convenience of a pill versus a weekly injection is a significant advantage for many patients.

Is oral semaglutide safe for elderly patients?

This study included patients aged 75 and older, who still showed meaningful HbA1c and weight reductions. While the elderly subgroup had slightly more adverse events (30.8% vs 23.4%), no new safety concerns were identified compared to younger patients.

Read the original research

PIONEER REAL Japan: Primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice.

Journal of diabetes investigation, 15(11), 1566-1577

View on PubMed ↗Publisher’s paper ↗

Citation

Yabe, Daisuke; Hamamoto, Yoshiyuki; Kawanami, Daiji; Nishimura, Rimei; Terauchi, Yasuo; Amadid, Hanan; Braae, Uffe Christian; Major-Pedersen, Atheline; Suzuki, Ryo. (2024). PIONEER REAL Japan: Primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice.. Journal of diabetes investigation, 15(11), 1566-1577. https://doi.org/10.1111/jdi.14291